Cargando…
A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany
Background: Worldwide, urothelial carcinoma (UC) is a common cause of morbidity and mortality. In particular, the incidence of bladder cancer varies widely across Europe; Germany has the ninth highest international age-standardized incidence. For advanced UC or metastatic UC (mUC), platinum-based co...
Autores principales: | Niegisch, Günter, Gerullis, Holger, Lin, Shih-Wen, Pavlova, Julie, Gondos, Adam, Rudolph, Anja, Haas, Gabriele, Hennies, Nora, Kramer, Mario W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929077/ https://www.ncbi.nlm.nih.gov/pubmed/29721042 http://dx.doi.org/10.7150/jca.23162 |
Ejemplares similares
-
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019) -
Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021) -
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014) -
Metastatic penile carcinoma – an update on the current diagnosis and treatment options
por: Barski, Dimitri, et al.
Publicado: (2014) -
Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)